Valuation: Natera, Inc.

Market Cap 39.72B 34.73B 32.04B 29.45B 55.8B 3,822B 56.76B 382B 150B 1,868B 149B 146B 6,439B P/E 2026 *
-166x
P/E 2027 * -1,200x
Enterprise Value 38.7B 33.84B 31.21B 28.69B 54.36B 3,724B 55.29B 373B 146B 1,820B 145B 142B 6,273B EV / Sales 2026 *
13.8x
EV / Sales 2027 * 11.5x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day+1.73%
1 week+1.09%
Current month+2.18%
1 month+27.84%
3 months+33.87%
6 months+15.41%
Current year+21.07%
1 week 261.63
Extreme 261.63
283.87
1 month 217.72
Extreme 217.72
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Director/Board Member 52 2006-12-31
Director/Board Member 78 2017-01-31
Director/Board Member 55 2019-08-14
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Founder

-1,000 0.0007%
06-30Sell

General Counsel

-16,800 0.0117%
06-30Sell

Executive/Senior Manager

-3,000 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+1.73%+1.09%+85.10%+459.67% 39.72B
-1.34%-2.07%+10.72%+27.83% 22.3B
+1.21%+1.78%-20.31%-39.66% 7.43B
-2.18%-6.37%+10.73%+96.76% 4.83B
+0.55%+2.86%+16.07%+48.18% 2.99B
+5.94%+0.79%-19.04%+884.23% 1.96B
+1.90%+1.83%+110.14%-15.99% 1.89B
+3.85%+22.13%-3.31%-63.38% 1.92B
+3.37%+9.73%+34.98%-18.27% 1.85B
+0.61%+7.14%+29.29%+7.84% 1.77B
Average +1.42%+3.94%+25.44%+138.72% 8.67B
Weighted average by Cap. +0.43%+0.57%+44.42%+239.56%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.26B 2.07B 3.93B 269B 4B 26.93B 10.57B 132B 10.5B 10.27B 453B 3.33B 2.91B 2.68B 2.47B 4.68B 320B 4.76B 32.05B 12.57B 157B 12.5B 12.22B 540B
Net income -225M -197M -181M -167M -316M -21.64B -321M -2.16B -849M -10.57B -844M -826M -36.45B -28.74M -25.13M -23.18M -21.31M -40.37M -2.77B -41.06M -277M -109M -1.35B -108M -106M -4.66B
Net Debt -1.02B -895M -826M -759M -1.44B -98.52B -1.46B -9.86B -3.87B -48.15B -3.85B -3.76B -166B -1.3B -1.14B -1.05B -966M -1.83B -125B -1.86B -12.55B -4.92B -61.29B -4.89B -4.79B -211B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-15 US$277.37 +1.73% 867,755
26-07-14 US$272.66 -0.08% 954,842
26-07-13 US$272.89 +1.09% 1,528,001
26-07-10 US$269.95 -4.22% 969,803
26-07-09 US$281.85 +2.72% 1,958,307
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
277.37USD
Average target price
279.76USD
Spread / Average Target
+0.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock